Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 359.97% | 215.79% | 3,186.63% | 7.38% | -280.02% |
| Total Depreciation and Amortization | -5.73% | -5.74% | -4.15% | -3.77% | -2.91% |
| Total Amortization of Deferred Charges | 69.12% | 37.47% | 23.09% | 18.70% | 29.46% |
| Total Other Non-Cash Items | -216.59% | -146.25% | -326.61% | -2,728.03% | 2,190.86% |
| Change in Net Operating Assets | -133.07% | -127.12% | -165.43% | -25.68% | 120.40% |
| Cash from Operations | 137.94% | 133.58% | -49.14% | -58.36% | 15.91% |
| Capital Expenditure | 83.99% | 75.85% | 75.18% | 24.31% | -22.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -52.99% | -251.72% | -160.00% | -248.58% | -16.56% |
| Cash from Investing | -59.27% | -253.02% | -162.64% | -244.97% | -2.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,030,123.33% | -419,444.44% | -453,008.00% | -471,883.33% | -7.14% |
| Issuance of Common Stock | -43.22% | -44.42% | -53.76% | -30.13% | 159.81% |
| Repurchase of Common Stock | -779.94% | -241.87% | -378.95% | -657.37% | -222.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,138.22% | 12,955.04% | 13,855.40% | 4,801.43% | 721.68% |
| Cash from Financing | 1,008.63% | 422.16% | 340.83% | 436.48% | 183.28% |
| Foreign Exchange rate Adjustments | -145.66% | 1,213.27% | 301.54% | 271.88% | -- |
| Miscellaneous Cash Flow Adjustments | 200.00% | 200.00% | -- | -- | -- |
| Net Change in Cash | 1,795.89% | 3,289.40% | 107.93% | 73.12% | 580.59% |